Renaissance Technologies LLC Invests $866,000 in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Renaissance Technologies LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 38,700 shares of the company’s stock, valued at approximately $866,000.

A number of other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its stake in shares of Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares during the period. GAMMA Investing LLC increased its holdings in shares of Intellia Therapeutics by 1,322.0% during the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after purchasing an additional 2,459 shares during the period. EntryPoint Capital LLC increased its holdings in shares of Intellia Therapeutics by 61.1% during the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after purchasing an additional 1,563 shares during the period. Finally, AdvisorNet Financial Inc increased its holdings in shares of Intellia Therapeutics by 63.5% during the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock worth $114,000 after purchasing an additional 1,980 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.00% of the company’s stock.

Intellia Therapeutics Stock Down 0.8 %

Shares of NASDAQ:NTLA opened at $17.84 on Tuesday. Intellia Therapeutics, Inc. has a twelve month low of $17.43 and a twelve month high of $34.87. The firm has a market capitalization of $1.72 billion, a PE ratio of -3.33 and a beta of 1.76. The company has a 50-day moving average price of $21.82 and a two-hundred day moving average price of $23.41.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The business’s quarterly revenue was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.40) earnings per share. Analysts anticipate that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NTLA. Stifel Nicolaus decreased their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. JPMorgan Chase & Co. reduced their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. Finally, Truist Financial reissued a “buy” rating and set a $120.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.77.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.